In the international phase III, EURO EWING 2012 trial, published in the Lancet, standard U.S. chemotherapy regimen improved the clinical outcomes with fewer side effects compared to the standard European regimen in newly diagnosed patients with #Ewing sarcoma.

In this randomized trial, eligible patients were randomized (1:1) to either European regimen consisting of induction with VIDE (vincristine, ifosfamide, doxorubicin, etoposide) and consolidation regimens including VAI (vincristine, actinomycin D, ifosfamide), VAC (vincirstine/actinomycin D plus cyclophosphamide), and busulfan/melphalan or the U.S. regimen consisting of induction with compressed VDC (vincristine, doxorubicin, cyclophosphamide) plus IE (ifosfamide/etoposide) and consolidation regimens including IE, VC (vincristine/cyclophosphamide), VAI, and busulfan/melphalan, with treatment given in shorter duration compared to the European regimen.

After median follow-up of 47 months, Event-free survival at 3 years was 67% with the U.S. regimen vs 61% with the European regimen (adjusted hazard ratio [HR] = 0.71, 95% CI = 0.55–0.92).